Indication

Delay or failure of allogenic bone marrow transplant

Delay or failure of allogeneic bone marrow transplant is a life-threatening hematologic complication in patients who undergo allogeneic bone marrow or hematopoietic stem cell transplantation. Read more about Delay or failure of allogenic bone marrow transplant

3 drugs 3 manufacturers

Advertisement

Drugs that treat it

Common Delay or failure of allogenic bone marrow transplant therapies.

Showing 1–3 of 3 drugs

Filter & compare in the drug finder →Opens the drug finder with Delay or failure of allogenic bone marrow transplant preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Delay or failure of allogenic bone marrow transplant.

Delay or failure of allogeneic bone marrow transplant is a life-threatening hematologic complication in patients who undergo allogeneic bone marrow or hematopoietic stem cell transplantation.

It encompasses both primary graft failure, characterized by the prolonged absence of donor stem cell engraftment and sustained severe pancytopenia by day 28 to 42 post-transplant, and secondary graft failure, marked by a subsequent loss of donor hematopoiesis after initial successful engraftment.

Pathophysiologically, this clinical state is driven by immune-mediated host rejection, insufficient donor cell dose, poor graft function, or adverse microenvironmental factors such as opportunistic viral infections and drug toxicities, predisposing patients to severe infectious and hemorrhagic mortality.

Personalize your experience

Follow Delay or failure of allogenic bone marrow transplant and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it